key: cord-0930280-m12rwiry authors: Ying, Hao; Ebrahimi, Mohsen; Keivan, Mona; Khoshnam, Seyed Esmaeil; Salahi, Sarvenaz; Farzaneh, Maryam title: miRNAs; a novel strategy for the treatment of COVID‐19 date: 2021-07-05 journal: Cell Biol Int DOI: 10.1002/cbin.11653 sha: ec36b86434ae1d4bc2590a37058a608e6155d354 doc_id: 930280 cord_uid: m12rwiry Coronavirus disease 2019 (COVID‐19) is the seventh member of the bat severe acute respiratory syndrome family. COVID‐19 can fuse their envelopes with the host cell membranes and deliver their genetic material. COVID‐19 attacks the respiratory system and stimulates the host inflammatory responses, enhances the recruitment of immune cells, and promotes angiotensin‐converting enzyme 2 activities. Patients with confirmed COVID‐19 may have experienced fever, dry cough, headache, dyspnea, acute kidney injury, acute respiratory distress syndrome, and acute heart injury. Several strategies such as oxygen therapy, ventilation, antibiotic or antiviral therapy, and renal replacement therapy are commonly used to decrease COVID‐19‐associated mortality. However, these approaches may not be good treatment options. Therefore, the search for an alternative‐novel therapy is urgently important to prevent the disease progression. Recently, microRNAs (miRNAs) have emerged as a promising strategy for COVID‐19. The design of oligonucleotide against the genetic material of COVID‐19 might suppress virus RNA translation. Several previous studies have shown that host miRNAs play an antiviral role and improve the treatment of patients with COVID‐19. miRNAs by binding to the 3′‐untranslated region (UTR) or 5′‐UTR of viral RNA play an important role in COVID‐19‐host interplay and viral replication. miRNAs interact with multiple pathways and reduce inflammatory biomarkers, thrombi formation, and tissue damage to accelerate the patient outcome. The information in this review provides a summary of the current clinical application of miRNAs for the treatments of patients with COVID‐19. Wuhan (the capital of central China's Hubei province) and later spread worldwide (Bernheim et al., 2020; Diao et al., 2020; Lauer et al., 2019) . has been reported as the seventh member of the bat severe acute respiratory syndrome (SARS) family, which is known as SARS-CoV-2 (Lauer et al., 2019; Wang et al., 2020; Zhu et al., 2020) . Coronaviruses are enveloped positive-sense RNA viruses that generally cause mild to acute respiratory infection in various species from bats to humans (Chang et al., 2020; Chen, 2020; Fung et al., 2020; Song, 2020) . COVID-19 contains four structural proteins, including nucleocapsid (N) protein and membrane (M), spike (S), and small envelope (E) glycoproteins (Abu-Izneid et al., 2020) . These viruses directly fuse to the plasma membrane, deliver their genetic materials, and complete their life cycle (Cascella et al., 2020; Jan & Arif, 2020) . Initial symptoms for most patients with include fever, headache, shortness of breath, muscle soreness, sputum production, dyspnea, diarrhea, nausea, and fatigue (Bernheim et al., 2020; Huang et al., 2020; Jiang et al., 2020; Kui et al., 2020) . A slight decrease in platelet levels and a massive release of tumor necrosis factor (TNF), plasminogen activators, and interleukin-1 and 6 (IL-1 and IL-6) have been reported to stimulate acute endothelial cell activation and microthrombus in lung vascularity (Schultz et al., 2021) . COVID-19 infects the respiratory system, triggers widespread inflammation, promotes the recruitment of immune cells, and angiotensin-converting enzyme 2 (ACE2) activities (Abdi, 2020; Lauer et al., 2019) . In a subset of high-risk patients (patients with diabetes or preexisting cardiovascular diseases or hypertension), acute cardiac injury, acute kidney injury, acute respiratory distress F I G U R E 1 miRNA at cellular level due to COVID-19 infection. RNA polymerase II or III transcribed miRNA genes and generates pri-miRNAs (primary miRNAs). Subsequently, Drosha/DGCR8 holoenzyme (microprocessor cleavage) mediates processing of the pri-miRNA to generate the precursor miRNA (pre-miRNA) or a hairpin structured precursor (∼60-to 70 nt) in the nucleus. The pre-miRNAs by Exportin-5 (Exp5) and Ran-GTP (a nucleocytoplasmic transporter) are delivered to the cytoplasm. The pre-miRNAs hairpin cleaved into a ∼22 nucleotide duplex through Dicer (RNase III endonuclease) with the transactivating response RNA-binding protein (TRBP) to form a mature microRNA duplex. The mature miRNAs are created via RNA-induced silencing complex. miRNA binds with the AGO protein (RNA-induced silencing complex [RISC]) to target messenger RNA (mRNA) and trigger mRNA cleavage, mRNA degradation, and translation repression. COVID-19 contains four structural proteins, including nucleocapsid (N) protein and membrane (M), spike (S), and small envelope (E) glycoproteins. miRNAs by binding to the coding region or 5′-UTR of viral RNA play an important role in COVID-19-host interplay and viral replication. COVID-19, coronavirus disease 2019; miRNA, microRNA; UTR, untranslated region 2 | C Cell ell B Biology iology I International nternational syndrome (ARDS), and multiple organ dysfunction might be triggered Huang et al., 2020; Xu et al., 2020) . Till now, various therapeutic modalities such as antibiotic therapy, antiviral therapy, glucocorticoids therapy, invasive and noninvasive ventilation, and renal replacement therapy have been assessed in clinical settings for COVID-19 patients Chen et al., 2020; Heymann & Shindo, 2020; Huang et al., 2020; MacLaren et al., 2020; Wang et al., 2020; Zhou et al., 2020) . However, these strategies are not likely to be safe and effective treatment options against COVID-19 (Jean et al., 2020; Momekov & Momekova, 2020) . Therefore, the search for an alternative-novel therapy is urgently important to prevent the disease progression (Widiasta et al., 2020) . Recently, microRNAs (miRNAs) have been emerged as antiviral regulators of viral genes (Gong & Zhang, 2020; Huang et al., 2021; Ramaiah, 2020) . miRNAs through silencing genes play an important role in controlling the expression of transcription factors (Waheed & Zeng, 2020) . Hence, it may be feasible to use miRNAs to overcome COVID-19 (El-Nabi et al., 2020; Mishra et al., 2020) . miRNA-based therapeutic is a promising approach against heart failure or cardiovascular diseases, neurological disorders, tumorigenesis, and viral infection Cui et al., 2021; Takahashi et al., 2019) . RNA polymerase II or III transcribed miRNA genes and generates pri-miRNAs (primary miRNAs) (Borchert et al., 2006; Gregory et al., 2005) . Subsequently, Drosha/DGCR8 holoenzyme (microprocessor cleavage) mediates processing of the pri-miRNA to generate the precursor miRNA (pre-miRNA) or a hairpin structured precursor (∼60 to 70 nt) in the nucleus (Zeng et al., 2017) . The pre-miRNAs by Exportin-5 (Exp5) and Ran-GTP (a nucleocytoplasmic transporter) are delivered to the cytoplasm (Wu et al., 2018) . The pre-miRNAs hairpin cleaved into a ∼22 nucleotide duplex through Dicer (RNase III endonuclease) with the transactivating response RNA-binding protein to form a mature miRNA duplex (Fareh et al., 2016; Graves & Zeng, 2012; Ha & Kim, 2014) . The mature miRNAs are created via RNA-induced silencing complex (RISC) (Berezikov et al., 2007; Du & Zamore, 2005; Ruby et al., 2007) . (Garg et al., 2021; Hartmann et al., 2016) . Hence, the upregulation of these miRNAs might be a predictor of inflammation and myocardial damage (Garg et al., 2021) . Khan et al. (2020) showed that three host miRNAs, including has-miR-17-5p, has-miR-20b-5p, and hsa-miR-323a-5p had an antiviral effect against COVID-19. They suggested that miRNAs may specifically inhibit several Toll-Like receptors pathways to modulate the host antiviral defense mechanism. Guterres et al. (2020) Li et al. (2020) evaluated the expression of miRNAs in the peripheral blood from patient with COVID-19. They found that the expression of some miRNAs was increased (35 miRNAs) or decreased (38 miRNAs). Besides, the expression of three miRNAs, including miR-183-5p, miR-627-5p, and miR-144-3p was significantly decreased. Pontecorvi et al. (2020) reported that the sex hormones in human host cells play important roles in COVID-19 lethality. They presented seven gender-associated miRNAs, including hsa-let-7a-g/i, hsa-miR-98-5p, hsa-miR-145, hsa-miR-222, hsa-miR-19a/b-3p, hsa-miR-20b, and hsa-miR-106a, which were localized on the X-chromosome and participated in regulation of COVID-19 receptors and host immunity. These miRNAs were reported to target the TMPRSS2, ADAM17, and potent epigenetic regulators stimulate the innate and adaptive immune system and influence the viral propagation (Mukhopadhyay & Mussa, 2020) . However, different sets of miRNAs are expressed in the host system which target an entire immune pathway (Cho et al., 2020; Jia & Wei, 2020) . Also, various miRNAs with multi-step maturation need several strategies to enhance miRNAs function and develop miRNAs-based therapeutics against COVID-19 (Abu-Izneid et al., 2020) . Besides, manipulating endogenous miRNA to reduce the risk of COVID-19 infection may cause negative effects on the host genome (Ivashchenko et al., 2020; Mishra et al., 2020) . Recently, the viral-encoded miRNAs have been shown to target several signaling pathways and critical cellular processes such as transcription, metabolism, and defense (Demirci & Adan, 2020; Mishra et al., 2020) . Demirci and Adan (2020) factor kappa B activity and stimulated proinflammatory cytokines (Arisan et al., 2020) . Therefore, further investigation is required to identify specific miRNAs that target and stop virus-induced infection (Farshbaf et al., 2020; Pontecorvi et al., 2020) . Several previous studies identified the interactions between miRNA and SARS-CoV-2 and reported novel approaches against SARS-CoV-2 infection (Rizkita & Astuti, 2021) . It has also been reported that antiviral miRNAs (miR-24, miR-124, and miR-744) (Gasparello et al., 2021) . Miravirsen is a miR-122 antagonist and the first miRNA-based drug, which downregulates viral RNA levels (Santaris Pharma A/S, Phase II clinical trial) (Janssen et al., 2013; Okuyan & Begen, 2021) . Therefore, antagonist miR (an-timiR) and miR mimic could be innovative approach for the treatment of COVID-19 infections (Rizkita & Astuti, 2021 (Forman et al., 2021; Heaton, 2020) , in the case of miRNA-COVID-19 interaction, further experimental is still required to generate miRNA-based animal models of COVID-19 to improve vaccine efficacy. COVID-19 infection stimulates inflammation and endothelial cell damage in multiorgans with cardiac injury (Garg et al., 2021) . Viruses-derived miRNA can impact the host miRNA expression level and improve virus pathogenicity (Abu-Izneid et al., 2020) . Hostderived miRNAs play essential roles in limiting viral replication Wong et al., 2020) . There is evidence that miRNAs are able to downregulate the viral replication, modulate viral infectious progress, and enhance the survival rates in severe COVID-19 patients (Schultz et al., 2021) . miRNAs interact with multiple pathways and reduce inflammatory biomarkers, thrombi formation, and tissue damage to accelerate the patient outcome (Schultz et al., 2021) . According to the literature, the interaction of host miRNA with the COVID-19-encoded mRNAs may alter by age, underlying chronic disease (diabetes, lung, and cardiovascular disorders), and gender. Also, the ACE2, TMPRSS2, and ADAM17 genes might serve as potent targets in patients with COVID-19. However, more investigations are needed to confirm their interactions with miRNAs in COVID-19 and in other infectious events. None of the authors have any conflict of interest. Hao Ying, Mohsen Ebrahimi, and Maryam Farzaneh have been involved in drafting the manuscript. Mona Keivan, and Seyed Esmaeil Khoshnam have made substantial contributions to the revising of the manuscript and the design of the Table. Sarvenaz Salahi has made a substantial contribution to the writing and the design of the Figure. All authors read and approved the final manuscript. There is no data availability statement. Maryam Farzaneh http://orcid.org/0000-0001-6239-8745 6 | C Cell ell B Biology iology I International nternational Coronavirus disease 2019 (COVID-19) outbreak in Iran; actions and problems Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections miRCOVID-19: Potential targets of human miRNAs in SARS-CoV-2 for RNA-based drug discovery The prediction of miRNAs in SARS-CoV-2 genomes: hsa-miR databases identify 7 key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities MicroRNA involvement in signaling pathways during viral infection Mammalian mirtron genes Findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection miR-1207-5p can contribute to dysregulation of inflammatory response in COVID-19 via targeting SARS-CoV-2 RNA RNA polymerase III transcribes human microRNAs The impact of MicroRNAs (miRNAs) on the genotype of coronaviruses Features, evaluation and treatment coronavirus (COVID-19), in: StatPearls [Internet Coronavirus disease 2019: Coronaviruses and blood safety COVID-19: Fighting the invisible enemy with microRNAs Pathogenicity and transmissibility of 2019-nCoV-a quick overview and comparison with other emerging viruses Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases MicroRNAs and their targetomes in tumor-immune communication miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells, 9 Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates MiRNA in food simultaneously controls animal viral disease and human tumorigenesis Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection SARS-CoV-2 and miRNA-like inhibition power The roles of microRNAs in mouse development The novel coronavirus (COVID-19) infection in Hangzhou: An experience to share microPrimer: The biogenesis and function of microRNA A new approach for COVID-19 treatment by micro-RNA The role of miRNAs in COVID-19 disease TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy COVID-19 virulence in aged patients might be impacted by the host cellular MicroRNAs abundance/profile A tug-ofwar between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin Circulating cardiovascular microRNAs in critically ill COVID-19 patients Short title: MicroRNA signatures in COVID-19 Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs Biogenesis of mammalian microRNAs: A global view Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era Human RISC couples microRNA biogenesis and posttranscriptional gene silencing What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infection Regulation of microRNA biogenesis Covid-19, ACE2 and the kidney MicroRNA-based therapy of GATA2-deficient vascular disease New strategies for treatment of COVID-19 and evolution of SARS-CoV-2 according to biodiversity and evolution theory Challenges of developing novel vaccines with particular global health importance COVID-19: What is next for public health? The Lancet Implications of SARS-CoV-2 mutations for genomic RNA structure and host microRNA targeting Clinical features of patients infected with 2019 novel coronavirus in Wuhan Host microRNAs regulate expression of hepatitis B virus genes during transmission from patients' sperm to embryo MicroRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19 Angiotensin-converting enzyme 2 protects from severe acute lung failure How miRNAs can protect humans from coronaviruses COVID-19 Another coronavirus, Another challenge Treatment of HCV infection by targeting microRNA Treatment options for COVID-19: The reality and challenges Modulators of MicroRNA Function in the Immune System Review of the clinical characteristics of coronavirus disease 2019 (COVID-19) Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19 Expression analyses of microRNAs in Hamster lung tissues infected by SARS-CoV-2 Roles of small RNAs in the establishment of tolerant interaction between plants and viruses. Current Opinion in Virology Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province siRNA Versus miRNA as therapeutics for gene silencing The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Differential microRNA expression in the peripheral blood from human patients with COVID-19 miRNA-200c-3p is crucial in acute respiratory distress syndrome Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2 Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation Broad-spectrum inhibition of respiratory virus infection by microRNA mimics targeting p38 MAPK signaling The interplay between viral-derived miRNAs and host immunity during infection Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens Identification of novel hypothalamic microRNAs as promising therapeutics for SARS-CoV-2 by regulating ACE2 and TMPRSS2 expression: An in silico analysis Animal models for COVID-19 Potential role of cellular miRNAs in coronavirus-host interplay Overview of MicroRNA biogenesis, mechanisms of actions, and circulation miRNAs as attractive diagnostic and therapeutic targets for Familial Mediterranean Fever Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs microRNAs as new possible actors in gender disparities of Covid-19 pandemic Regulatory network of miRNA on its target: Coordination between transcriptional and post-transcriptional regulation of gene expression mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19 The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review Intronic microRNA precursors that bypass Drosha processing Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: An in silico analysis Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma 2019-nCoV 3C-Like Protease carries an activity-enhancing T285/A variation which may contribute to its high infectivity Development of miRNA-based therapeutic approaches for cancer patients MicroRNA biomarkers for infectious diseases: From basic research to biosensing MicroRNA regulation of RNA virus replication and pathogenesis Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation The critical role of miRNAs in regulation of flowering time and flower development A novel coronavirus outbreak of global health concern Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy Role of microRNAs in antiviral responses to dengue infection The role of exportin-5 in microRNA biogenesis and cancer Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series Annotation of miRNAs in COVID-19 coronavirus MicroRNA-like RNAs from the same miRNA precursors play a role in cassava chilling responses MicroRNAs expressed by human cytomegalovirus Host microRNAs and exosomes that modulate influenza virus infection Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses Patients Who Have Failed Low-Dose Therapy A novel coronavirus from patients with pneumonia in China